These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6601099)

  • 1. A simplified new method for HLA-DR typing using the TM1 monoclonal antibody.
    Grumet FC; Pask SB; Ness DB; Fendly BM; Engleman EG
    Hum Immunol; 1983 Feb; 6(2):63-73. PubMed ID: 6601099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [HLA class II typing of peripheral blood B lymphocytes separated using monoclonal antibodies].
    Lepage V; Raffoux C; Douay C; Mallet C; Colombani J
    Rev Fr Transfus Hemobiol; 1989 Apr; 32(2):135-40. PubMed ID: 2787994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A one-step monoclonal antibody typing procedure that simplifies HLA class I and class II typing.
    Lee JH; Lias M; Deng CT; Etessami S; Loon J; Chen M; Banh L; Conger N; Connors D; Manzo A
    Tissue Antigens; 1994 Jul; 44(1):34-42. PubMed ID: 7974466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation of B lymphocytes for HLA-DR typing using monoclonal antibodies.
    Bohnhoff C; Sawyer T; Blair A; Senitzer D
    J Immunol Methods; 1986 Jul; 91(2):175-80. PubMed ID: 3488349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA typing using IL-2 activated T lymphocytes: usefulness in pediatric candidates for allogeneic bone marrow transplantation.
    Kubo K; Tachino J; Ichikawa S; Hamamoto K; Ueda K
    Bone Marrow Transplant; 1991 Sep; 8(3):185-90. PubMed ID: 1720338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification by HLA typing of intrauterine-derived maternal T cells in four patients with severe combined immunodeficiency.
    Pollack MS; Kirkpatrick D; Kapoor N; Dupont B; O'Reilly RJ
    N Engl J Med; 1982 Sep; 307(11):662-6. PubMed ID: 7050708
    [No Abstract]   [Full Text] [Related]  

  • 7. Recognition of major histocompatibility complex class II antigens by two anti-HLA-DR monoclonal antibodies on canine marrow cells correlates with effects on in vitro and in vivo hematopoiesis.
    Yamaguchi M; McSweeney PA; Kimball L; Gersuk G; Hong DS; Kwok W; Storb R; Beckham C; Deeg HJ
    Transplantation; 1999 Oct; 68(8):1161-71. PubMed ID: 10551646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of HLA-DR antigens in antibody production: monoclonal anti-HLA-DR antibodies differ in their ability to directly inhibit B-cell response.
    Vazquez A; Charron D; Galanaud P
    Cell Immunol; 1982 Jul; 71(1):148-58. PubMed ID: 6215987
    [No Abstract]   [Full Text] [Related]  

  • 9. HLA-DR-antigen-associated restriction of EBV-specific cytotoxic T-cell colonies.
    Misko IS; Pope JH; Hütter R; Soszynski TD; Kane RG
    Int J Cancer; 1984 Feb; 33(2):239-43. PubMed ID: 6319303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mouse monoclonal antibody detects a new polymorphic Ia determinant other than HLA-DR antigen: a possible allele of DC-1.
    Maeda H
    Tissue Antigens; 1984 Mar; 23(3):163-70. PubMed ID: 6427972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of lymphocyte adhesion to human vascular endothelial cells in culture. T lymphocyte adhesion to endothelial cells through endothelial HLA-DR antigens induced by gamma interferon.
    Masuyama J; Minato N; Kano S
    J Clin Invest; 1986 May; 77(5):1596-605. PubMed ID: 3084562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression of HLA class II antigens in fetal human spleen: relationship of HLA-DP, DQ, and DR to immunoglobulin expression.
    Edwards JA; Durant BM; Jones DB; Evans PR; Smith JL
    J Immunol; 1986 Jul; 137(2):490-7. PubMed ID: 3522732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The active rosette mixed-lymphocyte reaction: an early marker of lymphocyte activation linked to HLA-D-DR differences.
    Wybran J; Dupont E
    Clin Immunol Immunopathol; 1983 Apr; 27(1):51-5. PubMed ID: 6223752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of T-lymphoblast-encoded HLA-DR, MT, and SB antigens on human T-B lymphoblast hybrids.
    Howell DN; Hartzman RJ; Cresswell P
    Hum Immunol; 1983 Oct; 8(2):167-75. PubMed ID: 6417070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility of serologic HLA-DR antigen identification using activated T lymphocytes.
    Adams PW; Ferguson RM; Vaidya S; Orosz CG
    Hum Immunol; 1986 Jul; 16(3):295-303. PubMed ID: 3522503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The separation of cell populations using monoclonal antibodies attached to sepharose.
    de Kretser TA; Bodmer JG; Bodmer WF
    Tissue Antigens; 1980 Oct; 16(4):317-25. PubMed ID: 6936871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal mouse anti-I-Ak and anti-I-Ek antibodies cross-reacting with HLA-DR supertypic and subtypic determinants rather than classical DR allelic specificities.
    Pierres M; Mercier P; Madsen M; Mawas C; Kristensen T
    Tissue Antigens; 1982 Apr; 19(4):289-300. PubMed ID: 6179258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Requirement of Ia-positive accessory cells in the MLR response against class II antigen on human B cell tumor line.
    Yamamoto M; Yano A
    J Immunol; 1985 Dec; 135(6):3887-96. PubMed ID: 2999233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response of human T lymphocytes to phytohemagglutinin (PHA) after sequential depletion of monocytes, HLA-DR+, Leu11a+, and Leu7+ cells.
    Ulmer AJ; Scholz W; Ernst M; Flad HD
    Immunobiology; 1985 Dec; 170(5):419-33. PubMed ID: 2936677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Class II major histocompatibility complex antigen expression and cellular interactions in thyroid glands of Graves' disease.
    Matsunaga M; Eguchi K; Fukuda T; Kurata A; Tezuka H; Shimomura C; Otsubo T; Ishikawa N; Ito K; Nagataki S
    J Clin Endocrinol Metab; 1986 Apr; 62(4):723-8. PubMed ID: 3081570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.